NKTX Stock Overview
A clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Nkarta, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.53 |
| 52 Week High | US$16.24 |
| 52 Week Low | US$2.45 |
| Beta | 0.87 |
| 11 Month Change | -40.61% |
| 3 Month Change | -51.44% |
| 1 Year Change | -3.07% |
| 33 Year Change | -85.43% |
| 5 Year Change | n/a |
| Change since IPO | -94.72% |
Recent News & Updates
Nkarta: Catalysts Ahead, But Competition In Cell Therapy Too (Rating Downgrade)
Oct 31We're Hopeful That Nkarta (NASDAQ:NKTX) Will Use Its Cash Wisely
Sep 10
Nkarta: NK Cell Therapy Biotech With Good Standing Targeting R/R NHL Patients
Aug 14Recent updates
Nkarta: Catalysts Ahead, But Competition In Cell Therapy Too (Rating Downgrade)
Oct 31We're Hopeful That Nkarta (NASDAQ:NKTX) Will Use Its Cash Wisely
Sep 10Nkarta: NK Cell Therapy Biotech With Good Standing Targeting R/R NHL Patients
Aug 14Nkarta: A Look Into Q1 Results And Upcoming Catalysts
May 23Nkarta: Down 50% Since March With A Clinical Catalyst Ahead
Apr 27Nkarta: NK Cell Therapy Advancement On Two Fronts
Mar 25Nkarta: Possible Upside From H1 Update, If Positive
Jan 25Here's Why We're Watching Nkarta's (NASDAQ:NKTX) Cash Burn Situation
Jan 16We're Keeping An Eye On Nkarta's (NASDAQ:NKTX) Cash Burn Rate
Oct 04We Think Nkarta (NASDAQ:NKTX) Can Afford To Drive Business Growth
Jun 21We Think Nkarta (NASDAQ:NKTX) Can Afford To Drive Business Growth
Mar 06Here's Why We're Not Too Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Situation
Nov 20Nkarta GAAP EPS of -$0.61
Aug 11We're Not Very Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Rate
Jun 09Nkarta: A Promising Natural Killer Cell Play
May 20We Think Nkarta (NASDAQ:NKTX) Can Afford To Drive Business Growth
Aug 23Nkarta (NASDAQ:NKTX) Is In A Good Position To Deliver On Growth Plans
May 10Nkarta gets greenlight from the FDA for NKX019 cancer study
Apr 28We're Not Very Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Rate
Jan 25
Shareholder Returns
| NKTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -20.7% | -10.8% | -2.1% |
| 1Y | -3.1% | 13.9% | 30.2% |
Return vs Industry: NKTX underperformed the US Biotechs industry which returned 13.9% over the past year.
Return vs Market: NKTX underperformed the US Market which returned 30.2% over the past year.
Price Volatility
| NKTX volatility | |
|---|---|
| NKTX Average Weekly Movement | 11.0% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: NKTX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: NKTX's weekly volatility has decreased from 18% to 11% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 159 | Paul Hastings | www.nkartatx.com |
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company’s lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors.
Nkarta, Inc. Fundamentals Summary
| NKTX fundamental statistics | |
|---|---|
| Market cap | US$178.54m |
| Earnings (TTM) | -US$110.61m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.6x
P/E RatioIs NKTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NKTX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$110.61m |
| Earnings | -US$110.61m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.57 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did NKTX perform over the long term?
See historical performance and comparison